Drugs & Therapy Perspectives

, Volume 17, Issue 4, pp 8–11

Adjunctive therapy with antiplatelet agents prevents stent thrombosis

New drugs and disease management

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gruberg L, Dangas G, Leon MB. Coronary artery stents: appropriate use of adjunctive pharmacotherapy to prevent stent thrombosis. Drugs Aging 1999; 15(5): 341–8PubMedCrossRefGoogle Scholar
  2. 2.
    Steinhubl SR, Lincoff MA. Antithrombotic therapy with intracoronary stenting. Heart 1997; 78 Suppl. 2: 21–3PubMedGoogle Scholar
  3. 3.
    Theroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin?. Am Heart J 1997; 134: S62–70PubMedCrossRefGoogle Scholar
  4. 4.
    Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676–88PubMedCrossRefGoogle Scholar
  5. 5.
    Karillon G, Morice MC, Benveniste E, et al. Intravascular stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French multicenter registry. Circulation 1996; 94: 1519–27CrossRefGoogle Scholar
  6. 6.
    Morice MC, Valeix B, Marco J, et al. Preliminary results of the MUST Trial: major clinical events during the first month. J Am Coll Cardiol 1996; 27 Suppl. A: 137ACrossRefGoogle Scholar
  7. 7.
    Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394–405PubMedGoogle Scholar
  8. 8.
    Leon MB, Bairn DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339: 1665–71PubMedCrossRefGoogle Scholar
  9. 9.
    Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334(17): 1084–9PubMedCrossRefGoogle Scholar
  10. 10.
    Berger PB. Aspirin, ticlopidine and clopidogrel in and out of the catheterization laboratory. J Invasive Cardiol 1999; 11 Suppl. A: 20A–9PubMedGoogle Scholar
  11. 11.
    Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000; 60(2): 347–77PubMedCrossRefGoogle Scholar
  12. 12.
    Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000 Aug 8; 102(6): 624–9PubMedCrossRefGoogle Scholar
  13. 13.
    Bertrand ME, Rupprecht HJ, Urban P, et al. Comparative safety of ticlopidine and clopidogrel in coronary stent patients: data from CLASSICS [abstract]. Circulation 1999; 100 Suppl. 1: 1–620CrossRefGoogle Scholar
  14. 14.
    Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 128: 541–4PubMedGoogle Scholar
  15. 15.
    Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999; 281: 806–10PubMedCrossRefGoogle Scholar
  16. 16.
    The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87–92CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations